seems some of the shorts are finally coming around to the fact that you can't make arguments against a practical drug. c-diff is terrible, the patient population most vulnerable to it is expanding exponentially, and recurrence (which is addressed by Dificid) is a major problem for hospitals, nursing homes and other congregate living/treatment arrangements. imo, patients are the ones who suffer most - both emotionally and physically - from the use of "traditional remedies(?)" to treat the infection. good luck, and do your own DD before investing.